Jonathan Kay

Summary

Publications

  1. pmc Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
    Jonathan Kay
    Division of Rheumatology, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, USA
    Core Evid 4:159-70. 2010
  2. doi ACR/EULAR 2010 rheumatoid arthritis classification criteria
    Jonathan Kay
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Rheumatology (Oxford) 51:vi5-9. 2012
  3. doi Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012
    Jonathan Kay
    UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Biologicals 40:517-27. 2012
  4. pmc Biosimilars: a regulatory perspective from America
    Jonathan Kay
    UMass Memorial Medical Center, Rheumatology Center, Memorial Campus, 119 Belmont Street, Worcester, MA 01605, USA
    Arthritis Res Ther 13:112. 2011
  5. doi Evolution of treatment for rheumatoid arthritis
    Katherine S Upchurch
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01605, USA
    Rheumatology (Oxford) 51:vi28-36. 2012
  6. doi Assessment of control of rheumatoid arthritis disease activity
    Karen I Salomon-Escoto
    University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, USA
    Best Pract Res Clin Rheumatol 25:497-507. 2011

Detail Information

Publications7

  1. pmc Golimumab: A novel human anti-TNF-alpha monoclonal antibody for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis
    Jonathan Kay
    Division of Rheumatology, UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, MA, USA
    Core Evid 4:159-70. 2010
    ..However, golimumab has the potential advantage of once monthly subcutaneous administration and the possibility of both subcutaneous and intravenous administration...
  2. doi ACR/EULAR 2010 rheumatoid arthritis classification criteria
    Jonathan Kay
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
    Rheumatology (Oxford) 51:vi5-9. 2012
    ....
  3. doi Health Canada/BIOTECanada Summit on regulatory and clinical topics related to subsequent entry biologics (biosimilars), Ottawa, Canada, 14 May 2012
    Jonathan Kay
    UMass Memorial Medical Center, University of Massachusetts Medical School, Worcester, Massachusetts 01605, USA
    Biologicals 40:517-27. 2012
    ....
  4. pmc Biosimilars: a regulatory perspective from America
    Jonathan Kay
    UMass Memorial Medical Center, Rheumatology Center, Memorial Campus, 119 Belmont Street, Worcester, MA 01605, USA
    Arthritis Res Ther 13:112. 2011
    ..This paper reviews the processes for approval of biosimilars in the US and the European Union and highlights recent changes in federal regulations governing the approval of biosimilars in the US...
  5. doi Evolution of treatment for rheumatoid arthritis
    Katherine S Upchurch
    Division of Rheumatology, Department of Medicine, University of Massachusetts Medical School, 55 Lake Avenue North, Worcester, MA 01605, USA
    Rheumatology (Oxford) 51:vi28-36. 2012
    ..Current therapy for RA is such that progression from symptom onset to significant disability is now no longer inevitable, and RA patients can anticipate comfortable and productive lives on medical therapy...
  6. doi Assessment of control of rheumatoid arthritis disease activity
    Karen I Salomon-Escoto
    University of Massachusetts Medical School, Rheumatology Center, UMass Memorial Medical Center, Worcester, USA
    Best Pract Res Clin Rheumatol 25:497-507. 2011
    ..Because no single measure of RA disease activity fully quantifies the global burden of disease, rheumatologists must follow multiple parameters to assess disease activity thoroughly and to adjust treatment optimally...